---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000028"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-05-23T23:59:59+00:00"
generated_at: "2026-06-25T08:29:12.610927+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting

## Summary
- Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.
- Advisory vote on executive compensation passed with 92.76% support.
- Amended and restated 2020 Equity Incentive Plan and ESPP approved (89% and 99.6% of votes cast, respectively).
- Ernst & Young LLP ratified as independent auditor for fiscal 2022 with 93.28% approval.

## SEC filing metadata
- accession: 0000914475-22-000028
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-05-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/0000914475-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/nbix-20220518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000028
- JSON: https://secwatch.observer/filing/0000914475-22-000028.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.